Oxazolidinones occupy a special place in modern medicinal chemistry. The five-membered ring, containing both a nitrogen and an oxygen atom adjacent to a carbonyl, appears in approved antibiotics and in countless molecules moving through drug discovery pipelines. Of particular urgency are the 5-(S)-aminomethyl oxazolidinones, scaffolds central to next-generation antibiotics designed to combat multidrug-resistant and extensively drug-resistant strains of Mycobacterium tuberculosis, the pathogen behind one of the deadliest infectious diseases on Earth. As resistance spreads, the demand for efficient ways to assemble these rings has grown correspondingly sharper.

The trouble, historically, has been chirality. Molecules like oxazolidinones are three-dimensional objects, and their biological activity depends exquisitely on the handedness of their stereocentres. Conventional synthetic routes have leaned on the so-called chiral pool strategy, in which enantiopure amino alcohols harvested from natural sources serve as the key starting intermediates. That approach works, but it constrains chemists to the structural inventory of nature and demands lengthy sequences of functional group manipulations. Many methods exist to set the stereocentre at the 4-position of the ring, alpha to nitrogen, yet strategies for installing the 5-stereocentre, alpha to oxygen, have remained underdeveloped, leaving a stubborn gap in the synthetic toolbox.

The Caltech and Pittsburgh teams closed that gap with a two-stage reaction sequence performed by a single engineered enzyme. The cascade begins with aziridination, a transformation in which a nitrogen atom, delivered as a nitrene, is inserted across a carbon-carbon double bond to form a three-membered aziridine ring. The enzyme then guides a ring expansion of that strained intermediate, and the aziridine rearranges into the five-membered oxazolidinone. The result is a direct, enantioselective synthesis of clinically relevant and discovery-stage oxazolidinones starting from the simplest possible feedstocks: plain alkenes.

The choice of catalyst reflects a larger trend in synthetic biology. Haemproteins, enzymes built around an iron-containing porphyrin cofactor, have emerged in recent years as remarkably tunable platforms for carbene and nitrene transfer chemistry, reactions that no natural enzyme performs natively. Under the directed evolution methods pioneered in Arnold’s laboratory, researchers mutate and screen these proteins iteratively until the active site, originally shaped by evolution for tasks such as oxygen insertion, learn to conduct entirely new chemical transformations with high selectivity. In the new work, mutations introduced through directed evolution proved to be the decisive factor in controlling which mirror-image product the reaction delivers.

What makes the achievement stand out within the biocatalysis community is the class of alkene substrates involved. Until now, haemprotein-catalysed nitrene transfer has been largely restricted to conjugated systems such as styrenes, alkenes whose electronic character makes them reactive and easy to control. Unactivated alkenes, the saturated, electronically inert double bonds that pepper the structures of fats, terpenes, and countless pharmaceutical precursors, have resisted this chemistry. By extending nitrene transfer to these unactivated substrates, the new work substantially broadens the reach of enzymatic nitrene chemistry and opens a much wider swath of chemical space to biocatalytic functionalisation.

Behind the laboratory results lies a computational story. The team carried out detailed computational analysis of the reaction mechanism and found that the key mutations installed during directed evolution are directly responsible for the enantioselective formation of the products. In other words, the protein scaffold does not merely accelerate the reaction; specific amino acid substitutions sculpt the active site geometry so that the aziridination and ring expansion proceed with the precise three-dimensional outcome needed for the drug-like scaffold. This mechanistic understanding, developed jointly with Liu’s computational group at Pittsburgh, illustrates how theory and laboratory evolution now reinforce one another in modern enzyme design.

The practical implications are considerable. Because the cascade starts from simple alkenes and delivers enantioenriched oxazolidinones directly, it offers medicinal chemists a shorter, more modular path to analogues of clinically validated antibiotic scaffolds. Speeding access to structural variants matters enormously in anti-infective research, where teams must explore hundreds of derivative molecules to optimise potency, safety, and pharmacokinetics before a candidate can enter development. A route that removes the dependence on chiral-pool amino alcohols and sets the difficult 5-stereocentre in a single enzymatic operation could meaningfully compress discovery timelines for drugs aimed at resistant tuberculosis and beyond.

The study also adds a chapter to the broader narrative of enzyme engineering as a general-purpose tool for chemistry. Over the past two decades, the Arnold laboratory and others have shown that haemproteins can be reprogrammed to catalyse reactions absent from biology, including cyclopropanation, silicon-carbon bond formation, and a widening repertoire of nitrogen-transfer chemistry. Each extension of this platform challenges the traditional boundary between biological and abiological synthesis. The direct construction of oxazolidinone rings from unactivated alkenes now joins that list, and it does so with an added mechanistic account of how engineered mutations translate into stereochemical control.

For a field racing against the spread of antimicrobial resistance, the work carries both immediate and long-term significance. In the near term, the biocatalytic cascade provides a validated route to the exact scaffolds needed for the next generation of tuberculosis therapeutics. Over the longer term, the demonstration that engineered haemproteins can tame unactivated alkenes in enantioselective nitrene transfer suggests that many other transformations once considered the exclusive province of transition-metal catalysis may fall within reach of programmed biology. As the authors note, the chemistry was peer-reviewed and accepted by Nature, and while the published version is an early-release article subject to further editorial refinement, its conclusions are citable and carry a permanent digital identifier, marking a milestone that synthetic chemists and drug hunters alike will be watching closely.

Subject of Research: Biocatalytic enantioselective synthesis of chiral oxazolidinones from unactivated alkenes using engineered haemproteins

Article Title: Chiral oxazolidinones via biocatalytic aziridination of unactivated alkenes

Article References: Li, Z.-Q., Hanley, D., Zhang, Y., Xie, P.-P., Wu, S. J., Qin, Z.-Y., Zhang, C., Alfonzo, E., Li, F.-Z., Brinkman-Chen, S., Liu, P., & Arnold, F. H. (2026). Chiral oxazolidinones via biocatalytic aziridination of unactivated alkenes. Nature. https://doi.org/10.1038/s41586-026-11169-0

Image Credits: AI Generated

DOI: 10.1038/s41586-026-11169-0

Keywords: biocatalysis, oxazolidinones, aziridination, nitrene transfer, directed evolution, haemproteins, antibiotics, tuberculosis, enantioselectivity, unactivated alkenes, enzyme engineering, drug discovery

The material at the center of the work is a two-dimensional metal-organic framework, or 2D MOF, built from zirconium nodes and the tritopic linker 1,3,5-tris(4-carboxyphenyl)benzene, known as H3BTB. These ultrathin crystalline sheets have attracted intense interest in recent years because of three properties that heterogeneous catalysis has historically lacked: atomic-level thickness, ultrahigh specific surface area and a population of active sites that are, by construction, almost fully exposed. Instead of burying catalytic centers deep inside a bulk solid where reactants struggle to reach them, a 2D MOF displays them across its flat surfaces, closer in spirit to the environment a soluble complex enjoys than to that of a conventional solid pellet.

What the team did was to functionalize this scaffold with derivatives of BINAP, the chiral bisphosphine ligand whose discovery helped launch modern asymmetric catalysis and earned a Nobel Prize in 2001. BINAP is what chemists call a privileged ligand: its rigid, twisted binaphthyl backbone imposes a defined chiral pocket on any metal it coordinates, steering reactions toward one mirror-image product over the other. In the new work, BINAP-derived ligands were immobilized within the 2D MOF structure, and the framework was then metallized with rhodium, the same metal that powers some of the most important industrial and pharmaceutical asymmetric transformations. The resulting material, dubbed Zr-BTB-L-Rh, constitutes a well-defined heterogeneous asymmetric catalyst in which the rhodium active species are atomically dispersed rather than clustered into nanoparticles.

That atomically dispersed character proved to be more than a structural nicety. Powder X-ray diffraction, scanning and transmission electron microscopy, atomic force microscopy, inductively coupled plasma-mass spectrometry and high-angle annular dark-field scanning transmission electron microscopy were among the techniques used to confirm that the hierarchical porous architecture survived the functionalization and metallization steps intact, with individual rhodium sites distributed throughout. In other words, the catalytic centers inside the framework sit in an environment that resembles a solution-phase complex far more closely than a metal surface, which is why the authors describe the setting as quasi-homogeneous.

The benchmark chosen to test the concept was the asymmetric Hayashi-Miyaura reaction, in which an arylboronic acid adds across 2-cyclohexen-1-one to form a carbon-carbon bond with defined chirality. This reaction is a mainstay of asymmetric synthesis, and a rhodium-BINAP combination is its classical catalyst system, so the comparison with the molecular version was direct and demanding. The heterogeneous Zr-BTB-L-Rh delivered yields above 99 percent and enantioselectivities above 99 percent, matching the selectivity thresholds that chemists usually regard as the gold standard for a practical asymmetric process. Producing essentially one mirror image of the product from a recoverable solid is precisely the outcome that decades of heterogenization efforts have been chasing.

The turnover number, a measure of how many product molecules a single catalytic site can produce, tells an even more striking story. At low catalyst loading, the framework-bound rhodium achieved a turnover number up to 99 times that of its homogeneous counterpart. This is not merely a modest improvement in efficiency; it means each active site in the MOF does nearly two orders of magnitude more chemical work before being retired. The likely explanation lies in the same combination of features the framework provides: every rhodium site is exposed, reactants can diffuse efficiently through the hierarchical pores, and the solid support stabilizes the metal species against the aggregation and decomposition pathways that often cap the lifetime of soluble complexes.

Recyclability, the original motivation for heterogenizing catalysts in the first place, held up as well. The team recovered the catalyst after each run and reused it across five consecutive cycles, during which both activity and enantioselectivity remained stable. For a chiral catalyst, maintaining enantioselectivity through repeated use is the harder of the two demands, because even small structural changes to the chiral pocket, such as ligand oxidation or metal leaching, typically show up first as erosion of product handedness. The stable performance across five runs suggests that the coordination environment inside the MOF remains chemically intact, with the rhodium staying bound to its BINAP-derived ligands rather than drifting out of the framework.

The broader significance of the study lies in its position within a growing effort to build catalytic materials that erase the boundary between homogeneous and heterogeneous regimes. Previous work has explored phosphine-functionalized MOFs, chiral porous hybrid solids for asymmetric hydrogenation, and BINAP-based frameworks for enantioselective cyclization, all pursuing the same idea of a solid material that behaves like a precisely engineered molecule. The new contribution shows that the two-dimensional geometry in particular, with its maximal site exposure and quasi-homogeneous microenvironment, can push that idea to quantitative performance levels that rival, and in turnover terms dramatically exceed, the molecular catalysts that inspired it.

Practically, the design points toward asymmetric synthesis routes in which the valuable rhodium and the even more valuable chiral ligand are capital equipment rather than consumables. In pharmaceutical manufacturing, where enantioselective steps are ubiquitous and metal residues in products are tightly regulated, a catalyst that combines near-perfect selectivity with easy separation and reuse could meaningfully change the economics of a process. The authors report no competing interests, and the structural characterization for the study was supported by the Analysis and Testing Center of Xuzhou University of Technology.

Challenges remain before such frameworks become routine tools. Scaling the synthesis of atomically thin MOF nanosheets, verifying long-term stability across far more than five cycles under real process conditions, and extending the platform beyond the Hayashi-Miyaura benchmark to the full breadth of rhodium-catalyzed asymmetric reactions are all open questions. But the demonstration that a 2D MOF can host BINAP-rhodium sites at 99 percent enantioselectivity with a hundredfold boost in turnover is a clear signal that the next generation of chiral catalysts may be less like dissolved molecules and more like engineered crystal sheets.

Subject of Research: Heterogeneous asymmetric catalysis using BINAP-functionalized 2D metal-organic frameworks with atomically dispersed rhodium active sites

Article Title: BINAP-Functionalized 2D Metal-Organic Frameworks for Heterogeneous Rh Catalysts

Article References: BINAP-Functionalized 2D Metal-Organic Frameworks for Heterogeneous Rh Catalysts. (n.d.). https://doi.org/10.1007/s10562-026-05528-9

Image Credits: AI Generated

DOI: 10.1007/s10562-026-05528-9

Keywords: asymmetric catalysis, heterogeneous catalyst, 2D metal-organic frameworks, BINAP, rhodium, Hayashi-Miyaura reaction, enantioselectivity, turnover number, zirconium MOF, quasi-homogeneous catalysis, chiral ligand immobilization, catalyst recycling

The new work, published in Nature Chemical Biology, tackles a problem that has frustrated the apoptosis field since BAX was first implicated in ischemic injury: the protein is a moving target. In healthy cells, BAX lounges in the cytosol as an inactive monomer, its lethal membrane-penetrating helices tucked away inside its own structure. Only when death signals accumulate does BAX undergo a dramatic conformational transformation, exposing its N-terminus, unfurling its ninth alpha helix, and migrating to the mitochondrial outer membrane, where it oligomerizes into pores. Small molecules that bind the resting state have been described before, but they tend to be weak, poorly characterized, or reactive with many unrelated proteins, making them unreliable tools and even less reliable medicines.

The team behind the new study took a different approach: rather than hunting for a generic binder, they engineered a covalent warhead aimed at a specific cysteine residue on the surface of inactive BAX. Covalent inhibitors have enjoyed a renaissance in recent years, most famously in the form of acrylamide-based drugs that target a non-catalytic cysteine in EGFR-mutant lung cancer. The strategy offers the allure of prolonged target engagement at low drug concentrations, but it carries a well-known risk: off-target reactivity with the many cysteine-rich proteins floating in any cell. The challenge, therefore, was to design a ligand whose reactivity is only unleashed in the precise geometric context of the BAX binding pocket.

That is where the concept of enantioselectivity becomes central. Small drug-like molecules typically exist as two enantiomers, mirror-image forms that are chemically identical in an achiral test tube but profoundly different in the chiral environment of a living cell. Enzymes, receptors, and protein binding pockets distinguish between these mirror images with exquisite sensitivity, often binding one form tightly while ignoring the other. The researchers exploited this principle twice over: first by synthesizing both enantiomers of their candidate inhibitor and then by demonstrating that only one of them engages BAX efficiently, while the opposite enantiomer is essentially inert. This one-handed specificity is a hallmark of a well-behaved chemical probe and stands in sharp contrast to earlier BAX inhibitors whose activity could not be cleanly separated from nonspecific protein damage.

The design process began with structural analysis of the inactive BAX monomer, using prior nuclear magnetic resonance structures and molecular docking to identify a pocket adjacent to a reactive cysteine. The team then iterated through a series of analogues, tuning the electrophilic warhead and the surrounding scaffold until they achieved a compound that reacts with BAX rapidly and selectively in competition assays against a broad panel of cysteine-containing proteins. Chemoproteomic experiments in cell lysates confirmed the selectivity on a proteome-wide scale, showing that the compound’s covalent footprint is dominated by BAX rather than by the hundreds of other cysteine residues available for reaction. This kind of global reactivity profiling has become the gold standard for validating covalent chemistry, and its successful application here lends substantial credibility to the probe.

With a selective inhibitor in hand, the researchers turned to functional testing. In cell culture, the compound protected cells from apoptotic death provoked by a variety of stresses, and the protection was abolished when BAX was removed or when a non-reactive analogue was substituted, establishing that the cytoprotective effect runs through the intended target. Biochemical assays showed that the covalently modified BAX can no longer expose its membrane-inserting helix or translocate to mitochondria in response to activating signals, effectively locking the protein in its harmless resting conformation. The modification also prevented BAX oligomerization, the downstream step that converts individual protein molecules into the pore-forming assemblies that rupture the mitochondrial membrane and release cytochrome c.

The most consequential experiments, however, were performed in living animals. In a mouse model of ischemia-reperfusion injury, a scenario that mirrors the cellular damage that follows a heart attack or stroke, administration of the active enantiomer significantly reduced tissue damage compared with vehicle controls. Critically, the mirror-image enantiomer, which lacks BAX reactivity in vitro, provided no protection, a rigorous in vivo control that ties the therapeutic benefit directly to the covalent engagement of BAX. Pharmacokinetic measurements confirmed that the compound reaches relevant tissues at concentrations sufficient to modify the target, and the treated animals tolerated the drug without overt toxicity, an encouraging early signal for a strategy that modifies a protein involved in fundamental cellular quality control.

Experts in the apoptosis field have long debated whether inhibiting BAX systemically is safe or even desirable, given the protein’s role in eliminating damaged or potentially cancerous cells. The new study does not resolve that debate, but it sharpens the terms of the discussion. Because the inhibitor is covalent and long-acting, dosing regimens could in principle be tailored to acute, short-term scenarios, such as the hours surrounding reperfusion therapy after a myocardial infarction, where transient BAX inhibition might salvage tissue without the long-term cancer risks that chronic suppression might entail. The authors’ demonstration that a single enantiomer drives the entire pharmacological effect also suggests that medicinal chemistry optimization can proceed with confidence, since the inactive mirror image provides a built-in negative control for every future experiment.

The work also carries broader lessons for chemical biology. Covalent inhibitors were once viewed as liabilities to be engineered out of drug candidates; today they are a deliberate design choice, provided that selectivity is demonstrated rigorously. The BAX program illustrates the full pipeline: structural insight to identify a ligandable site, warhead tuning to balance reactivity and selectivity, enantiomer pairing to isolate specific from nonspecific effects, chemoproteomics to survey the proteome, and animal models to test whether the molecular mechanism translates into tissue-level protection. Each step reinforces the others, and the resulting probe is far more than a tool; it is a proof of concept that a notoriously difficult, conformationally dynamic protein can be drugged with precision.

Looking ahead, the researchers and their colleagues face the familiar gauntlet of translation: optimizing potency and pharmacokinetics, assessing safety across longer time horizons, and identifying the clinical settings where BAX inhibition offers the greatest benefit at the least risk. Beyond ischemic injury, candidates include neurodegenerative conditions in which mitochondrial apoptosis contributes to neuronal loss, and organ transplantation, where protecting donor tissue from programmed death could extend viability and improve outcomes. Whatever the ultimate therapeutic destination, the demonstration that an enantioselective covalent inhibitor of BAX can confer cytoprotection in vivo marks a milestone in the long campaign to control the machinery of cell death, and it hands the field a chemical instrument of unprecedented specificity for dissecting BAX biology in health and disease.

Subject of Research: Development of an enantioselective covalent small-molecule inhibitor of the pro-apoptotic protein BAX that prevents mitochondrial apoptosis and provides cytoprotection in vivo.

Article Title: An enantioselective covalent inhibitor of BAX confers cytoprotection in vivo

Article References: An enantioselective covalent inhibitor of BAX confers cytoprotection in vivo. (n.d.). https://doi.org/10.1038/s41589-026-02297-9

Image Credits: AI Generated

DOI: 10.1038/s41589-026-02297-9

Keywords: BAX, apoptosis, covalent inhibitor, enantioselectivity, mitochondria, cytoprotection, ischemia-reperfusion injury, chemical biology, drug design, chemoproteomics, Nature Chemical Biology, cell death

The stakes are enormous. Many of the most biologically active molecules in medicine and agriculture exist as two enantiomers, mirror-image structures that can behave completely differently in living systems. One form of a drug may heal while the other causes harm, which is why regulatory agencies and pharmaceutical manufacturers demand enantiomerically pure products. Asymmetric catalysis answers that demand by using chiral metal complexes to steer bond formation toward one stereoisomer with high stereoselectivity, enantioselectivity, and regioselectivity. The field traces its origins to 1968, when Knowles and Horner, together with their coworkers, performed the first asymmetric catalytic reaction. Since then, the interplay between metal identity and ligand design has defined progress across pharmaceuticals, agrochemicals, and medicinal chemistry.

At the heart of the review sits BINAP, or 2,2′-bis(diarylphosphino)-1,1′-binaphthyl, the landmark chiral ligand discovered by Ryoji Noyori and Hidemasa Takaya. BINAP supplies axial chirality, conformational flexibility, and strong steric and electronic asymmetry, and its complexes with ruthenium and rhodium catalyze an extraordinarily broad set of hydrogenations of olefins, ketones, and allylic alcohols with enantioselectivities that typically exceed ninety percent. The review emphasizes that these catalysts combine large turnover numbers with practical scalability, a combination that has made them workhorses in the industrial production of medicines and derivatives of natural products. Precise stereochemical control, the authors stress, emerges from the conjunction of ligand design, catalyst-substrate interactions, and carefully tuned reaction conditions rather than from any single factor.

One particularly striking line of research surveyed involves rhodium nanoparticles stabilized by chiral BINAP ligands, prepared in a one-pot synthesis alongside their silica-supported analogues. Characterization by transmission electron microscopy, phosphorus-31 magic-angle spinning NMR, and infrared spectroscopy of adsorbed carbon monoxide revealed highly dispersed nanoparticles with narrowly distributed core sizes. In the asymmetric hydroformylation of styrene, the chiral stabilization of the nanoparticle surface produced a regioselectivity of 99:1 and enantioselectivities of up to fifty-nine percent, markedly outperforming conventional systems. The chelated (R)-BINAP ligand carves out a rigid chiral pocket on the nanocatalyst surface, demonstrating that chirality can be effectively imposed even on nanoparticulate metal clusters.

The review also dissects how counterions, often dismissed as chemical spectators, reshape the behavior of rhodium-BINAP hydrogenation catalysts. Combining single-crystal X-ray crystallography, NMR spectroscopy, and catalytic testing, researchers showed that different counterions yield distinct pseudo-first-order rate constants and enantioselectivities, and that solvent choice further modulates both kinetics and selectivity. Intriguingly, for the hydrogenation of dimethyl itaconate in propylene carbonate, the anion exerted no effect at all on either activity or enantioselectivity, underscoring that counterion influence is complex and substrate-dependent. Alongside this, ruthenium(II)-BINAP complexes, notably Ru(CH3COO)2[(R)- or (S)-BINAP], achieve nearly quantitative yields of saturated isoquinoline alkaloid precursors from 2-acyl-1-alkylidene-1,2,3,4-tetrahydroisoquinolines with high optical purity—and, remarkably, in the stereochemical sense opposite to that delivered by the analogous rhodium catalyst, a reversal that highlights how metal identity alone can flip asymmetric induction.

Beyond phosphines, the review turns to the oxazoline family, where bis-oxazoline ligands have earned a reputation for delivering good to high enantioselectivities across many catalytic asymmetric reactions. New C2-symmetric Isbut-Box ligands, synthesized from substituted bis(oxazolin-2-yl)methylpropene frameworks, were evaluated in copper(I)-catalyzed cyclopropanation of olefins, with density functional theory calculations illuminating solvent effects and the structure of the copper(I) complex. These systems achieve up to seventy percent enantioselectivity and seventy-two percent diastereoselectivity, while a copper complex derived from a tert-butyl bisoxazoline showed promising activity in the enantioselective cyclopropanation of styrene. The authors note that the enormous early promise of bis-oxazolines has spurred extensive modification of the framework, including stiff, cyclic 1,4-box backbones in both C2- and C1-symmetric variants designed to tighten stereochemical control further.

Oxazolines are also proving valuable beyond traditional solution-phase transformations. C2-symmetric bis(oxazoline) ligands serve as transient chiral auxiliaries for constructing enantiomerically pure bis-cyclometalated rhodium(III) complexes, which act as configurationally stable stereogenic catalysts in asymmetric photocatalysis. Using inexpensive beta-amino alcohols and a symmetrically disubstituted diethyl malonimidate salt, the chiral auxiliary complexes formed within a single hour at room temperature. In a parallel effort, a new class of triazolyl-oxazoline ligands combining a chiral 2-oxazoline with a 1,2,3-triazol-4-yl moiety was shown by X-ray diffraction to coordinate palladium(II) either as monodentate ligands through the oxazoline nitrogen or as N,N-chelators, generating cationic allyl complexes, neutral dimers, and mononuclear dichloro species—an adaptable coordination chemistry that widens the design space for chiral palladium catalysis.

Perhaps the most forward-looking section concerns BINOL, 1,1′-bi-2-naphthol, paired with abundant main-group metals. Recent work revealed an unusual chiral-at-metal mechanism in BINOL-aluminum asymmetric catalysis: an octahedral chiral aluminum complex, thermodynamically more favorable than the previously proposed aluminum hydride, operates through ligand-assisted hydride transfer. In the catalytic hydroboration of heteroaryl ketones with pinacolborane, the optimized conditions delivered ninety-nine percent yield and ninety-nine percent enantiomeric excess, producing chiral alcohols prized in pharmaceutical synthesis. Meanwhile, bifunctional BINOL and H8BINOL ligands catalyze the addition of diphenylzinc to aldehydes at room temperature without additives, and a related ligand promotes highly enantioselective TMSCN additions when combined with Me2AlCl, with yields spanning seventy-five to ninety-six percent across optimized solvent systems.

The review closes with bis(imine) systems, where a bidentate chiral bis(imine)-copper(II) triflate complex drives the 1,3-dipolar cycloaddition of nitrones to electron-deficient dipolarophiles with endo/exo ratios of up to 95:5 and enantioselectivities reaching ninety-nine percent—performance that outshines established TADDOL-titanium, bis-oxazoline magnesium, and BINAP-palladium systems for this transformation. Together, the authors argue, these results show that rational ligand design and metal-ligand cooperation are the twin engines of progress in asymmetric catalysis. They call for sustainable synthesis built on eco-friendly oxidants, solvents, and reaction conditions, and for deeper integration of mechanistic studies and computational chemistry to design the next generation of rigid, electronically tunable chiral catalysts capable of tackling the most demanding reactions in organic synthesis.

Subject of Research: Innovative chiral metal ligand architectures for asymmetric catalysis

Article Title: Review on innovative metal ligand architectures for asymmetric catalysis

Article References: Review on innovative metal ligand architectures for asymmetric catalysis. (n.d.). https://doi.org/10.1007/s44509-026-00035-x

Image Credits: AI Generated

DOI: 10.1007/s44509-026-00035-x

Keywords: asymmetric catalysis, chiral ligands, BINAP, BINOL, bis-oxazoline, enantioselectivity, hydrogenation, hydroformylation, rhodium nanoparticles, green chemistry, homogeneous catalysis, cyclopropanation